Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Robert Bonakdar MD, FAAFP, FACN
Robert Bonakdar MD, FAAFP, FACN Advisory Board
David Rakel MD, FAAFP
David Rakel MD, FAAFP Editor-in-Chief
Peter Lin MD, CCFP
Peter Lin MD, CCFP Associate Editor
See All Experts
story of the week
Published in Primary Care and
1 other channel

Journal Scan / Research · March 17, 2015

Glycemic Response and Tolerability of Dapagliflozin vs Glipizide in Patients With T2DM

Diabetes, Obesity & Metabolism

 

 Save  Recommend
 Share

Additional Info

Diabetes, Obesity & Metabolism
Long-Term Glycaemic Response and Tolerability of Dapagliflozin Versus a Sulphonylurea as Add-On Therapy to Metformin in Type 2 Diabetes Patients: 4-Year Data
Diabetes Obes Metab 2015 Mar 04;[EPub Ahead of Print], S Del Prato, M Nauck, S Durán-Garcia, L Maffei, K Rohwedder, A Theuerkauf, S Parikh

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading

Most Read This Week

Recently Updated